Bringing the Patient into the Equation: A Pilot CME Initiative on the Treatment of Acute Myeloid Leukemia — Issue 2 (Video Program)
Released June 2021
Featuring Dr Courtney D DiNardo's perspectives on her time spent speaking with patients with acute myeloid leukemia from the practices of community oncologists Drs KS Kumar and Andrew C Rettew. (Video Program)
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).
Consider the clinical and prognostic significance of specific cytogenetic and molecular alterations, and use this information to develop or refine current diagnostic testing algorithms and treatment strategies for patients with acute myeloid leukemia (AML).
Determine how age, performance status and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with various presentations of AML.
Appreciate the FDA approval of venetoclax for patients with newly diagnosed AML not eligible for intensive therapy, and discern how this agent can be optimally integrated into clinical management.
Assess published research data and investigator perspectives regarding the management of AML with an actionable genomic alteration (eg, FLT3, IDH1/2), and use this information to develop optimal treatment plans for patients.
Design a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies used in the management of AML in patients not eligible for induction therapy, to support quality of life and continuation of treatment.
Video Program: Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/BringingthePatientAML21/Issue2/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/BringingthePatientAML21/Issue2/Video.
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/BringingthePatientAML21/Issue2/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/BringingthePatientAML21/Issue2.
Clinical Investigator
Courtney D DiNardo, MD, MSCE
Associate Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Advisory Committee: Foghorn Therapeutics, Gilead Sciences Inc, Immune-Onc Therapeutics Inc, Novartis, Takeda Oncology; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astex Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Cleave Therapeutics, Daiichi Sankyo Inc, Immune-Onc Therapeutics Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Scientific Advisory Board with Stock Options: Notable Labs.
Consulting Oncologists
KS Kumar, MD
Physician Partner
Florida Cancer Specialists and Research Institute
No relevant conflicts of interest to disclose.
Andrew C Rettew, DO
Drexel University College of Medicine
McGlinn Cancer Institute, Tower Health
West Reading, Pennsylvania
Advisory Committee: Bristol-Myers Squibb Company.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Expiration date: June 2022
Case: A woman in her early 70s with acute myeloid leukemia (AML) and an IDH mutation receives venetoclax and azacitidine
Selection of patients for treatment with venetoclax/azacitidine versus intensive 7 + 3 chemotherapy; optimal application of venetoclax/azacitidine
Tolerability and side effects of venetoclax/azacitidine; testing for IDH mutations and choice of therapy for patients with AML and an IDH mutation
Duration of therapy and long-term outcomes with venetoclax/azacitidine; clinical research on combination therapy with venetoclax and oral hypomethylating agents (HMAs)
Treatment options for patients with AML who experience disease progression on venetoclax/azacitidine; use of IDH inhibitors for AML
Case: A woman in her mid-50s with a complex medical history is diagnosed with AML and receives 7 + 3 chemotherapy and gemtuzumab ozogamicin
Case: A man in his early 70s with AML and a FLT3-ITD mutation receives 7 + 3 chemotherapy and midostaurin
Optimal approach to the management of AML with FLT3 mutations
Impact of COVID-19 on the clinical care of patients with AML
Case: A man in his early 70s with AML with myelodysplasia-related changes and mutations in RUNX1, SRSF2, ASXL1 and IDH2 receives liposomal daunorubicin and cytarabine (CPX-351) followed by enasidenib
Activity and tolerability of CPX-351 for AML; patient selection
Choice between a venetoclax/HMA combination and an IDH inhibitor for patients with progressive AML and an IDH mutation
Feasibility and efficacy of stem cell transplantation in patients with relapsed AML; use and tolerability of glasdegib and low-dose cytarabine for AML